Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 26, 2023 08:30 ET | Source: Atreca, Inc.

Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery...
November 14, 2023 16:30 ET | Source: Atreca, Inc.

Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
September 21, 2023 08:00 ET | Source: Atreca, Inc.

Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross

SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
August 10, 2023 16:05 ET | Source: Atreca, Inc.

Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring

Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif.,...
June 05, 2023 08:00 ET | Source: Atreca, Inc.

Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting

Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated Phase 2 go/no-go...
May 10, 2023 16:05 ET | Source: Atreca, Inc.

Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
April 26, 2023 16:05 ET | Source: Atreca, Inc.

Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting

SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through...
April 13, 2023 08:00 ET | Source: Atreca, Inc.

Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
March 29, 2023 16:05 ET | Source: Atreca, Inc.

Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression...
March 23, 2023 17:00 ET | Source: Atreca, Inc.

Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...